2025 Partners
Check Out Our 2025 Partner:
CNS Pharmaceuticals
Expertise Partner
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of
anti-cancer drug candidates for the treatment of primary and metastatic central nervous system
malignancies. We are focused on developing novel drugs with the ultimate aim of advancing
treatments for patients with primary or secondary brain cancers.
Our lead drugs Berubicin and TPI-287 appear to cross the blood-brain barrier and kill tumor cells in the brain. These therapies represent potentially new treatments for patients with glioblastoma
multiforme (GMB), an aggressive and incurable form of brain cancer.
Pacific Marine Biotech
Expertise Partner
Pacific Marine Biotech is a biopharmaceutical company pioneering marine-based treatments for Glioblastoma Multiforme (GBM). Founded on the discovery of marine-derived products, we aim to harness the untapped potential of marine organisms to develop innovative therapies. Our flagship product, Immune 12, is advancing towards U.S. FDA approval for clinical trials, while Australian GBM trials are set to launch in late 2024. We are committed to bringing new hope to patients battling these challenging brain tumors.
BELAY DIAGNOSTICS
Innovation Partner
At Belay Diagnostics, our mission is to serve patients and those who care for them. We see the need to provide innovative tools to aid in the diagnosis and management of suspected brain and spinal cord tumors.
As a molecular diagnostics company, our high-performance Summitâ„¢ NGS liquid biopsy focuses on the detection of SNVs, MNVs, indels, and chromosome arm level loss/gain from DNA in genes known to be associated with CNS tumors. Our Vantageâ„¢ MGMT promoter methylation test ascertains MGMT methylation status. Both tests can be performed simultaneously with one 6mL sample of CSF.
Our test report informs diagnosis, therapeutic, and clinical trial options. Together, we can help patients find a path forward.
Renishaw
Exhibition Partner
Renishaw Neuro Solutions enables direct-to-target delivery for a broad range of applications. Using the neuroinfuseâ„¢ drug delivery system, predictable and translatable therapy infusions in R&D and clinical trials can become a reality. Our Lab2Clinicâ„¢ service supports pharma through the R&D journey, translating into clinical trials and scaled-up commercialisation. We have a wide geographical reach, and we focus on promoting long-term partnerships. All this is underpinned by our FDA-cleared, CE-marked stereotatic products borne out of a +50-year precision engineering heritage.
End Brain Cancer Initiative
Exhibition Partner
The End Brain Cancer Initiative (EBCI), formerly the Chris Elliott Fund, www.EndBrainCancer. org, is a 501 (c)3 non-profit Patient Advocacy organization focused on early drug development and increasing patient and care partner access to advanced treatments, diagnostics, devices, technology, clinical trials, etc. and on advancing and turning science and data into additional FDA approved treatment options for cancer patients, including patients with brain tumors, brain cancer and metastasized disease to the brain and again, increasing patient access through commercialization and reimbursement efforts.
ANGLE
Exhibition Partner
ANGLE’s innovative circulating tumour cell (CTC) DDR pharmacodynamic biomarker assays, γH2AX, pKAP1, RAD51 and micronuclei, can detect even low levels of DNA damage, making them reliable biomarkers in clinical research. Our GCP-compliant service and R&D laboratories provide biomarker screening services and can develop DDR-specific biomarker assays tailored to your needs. Our patented FDA cleared Parsortix® technology ensures superior CTC liquid biopsy analysis for use in DDR clinical trials.
Telix
Exhibition Partner
Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation. Our products use targeted radiation to image disease and deliver truly personalized therapy in areas of significant unmet medical need. Telix’s theranostic pipeline aims to address significant unmet medical need in prostate, kidney, brain, and blood cancers, and a range of rare diseases.